Indian journal of ophthalmology · 2026
Evaluation of iStent® Inject W in mild to moderate primary open-angle glaucoma - Indian data on pseudophakic eyes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paul Chandrima, Paul Anujeet, Faruque Nusrat
Аннотация
PURPOSE: This study aimed to evaluate the safety and efficacy of standalone bilateral iStent® Inject W implantation in pseudophakic patients with mild to moderate primary open-angle glaucoma (POAG) over 18 months.
DESIGN: Prospective, longitudinal study.
METHODS: Twenty-eight pseudophakic eyes with mild to moderate POAG were implanted with iStent® Inject W. Outcome measures included intraocular pressure (IOP) and change in the number of antiglaucoma medications.
RESULTS: The mean IOP declined from 21.14 ± 2.18 mmHg preoperatively to 15.14 ± 1.51 mmHg at 18 months postoperatively ( P < 0.0001), while the average number of antiglaucoma medications was reduced from 2.07 ± 0.73 to 1.18 ± 0.83 over the same period ( P < 0.05).
CONCLUSION: Standalone iStent® Inject W implantation in pseudophakic patients with mild to moderate POAG results in a sustained reduction in IOP and the number of antiglaucoma medications at 18 months postoperatively.
DESIGN: Prospective, longitudinal study.
METHODS: Twenty-eight pseudophakic eyes with mild to moderate POAG were implanted with iStent® Inject W. Outcome measures included intraocular pressure (IOP) and change in the number of antiglaucoma medications.
RESULTS: The mean IOP declined from 21.14 ± 2.18 mmHg preoperatively to 15.14 ± 1.51 mmHg at 18 months postoperatively ( P < 0.0001), while the average number of antiglaucoma medications was reduced from 2.07 ± 0.73 to 1.18 ± 0.83 over the same period ( P < 0.05).
CONCLUSION: Standalone iStent® Inject W implantation in pseudophakic patients with mild to moderate POAG results in a sustained reduction in IOP and the number of antiglaucoma medications at 18 months postoperatively.